402 related articles for article (PubMed ID: 37302734)
1. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
[TBL] [Abstract][Full Text] [Related]
2. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
[TBL] [Abstract][Full Text] [Related]
3. Subcellular elements responsive to the biomechanical activity of triple-negative breast cancer-derived small extracellular vesicles.
Senigagliesi B; Bedolla DE; Birarda G; Zanetti M; Lazzarino M; Vaccari L; Parisse P; Casalis L
Biomol Concepts; 2022 Jan; 13(1):322-333. PubMed ID: 36482512
[TBL] [Abstract][Full Text] [Related]
4. A MCL-1-targeted photosensitizer to combat triple-negative breast cancer with enhanced photodynamic efficacy, sensitization to ROS-induced damage, and immune response.
Huang K; Yao H; Yan M; Zhang H; Yuan G; Wang Q; Xue J; Li J; Chen J
J Inorg Biochem; 2022 Dec; 237():111997. PubMed ID: 36137402
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer treatment in xenograft models by bifunctional nanoprobes combined to photodynamic therapy.
Dos Santos Jesus VP; Vieira PFA; Cintra RC; Sant'Anna LB; Zezell DM; Castilho ML; Raniero L
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102796. PubMed ID: 35263669
[TBL] [Abstract][Full Text] [Related]
6. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
[TBL] [Abstract][Full Text] [Related]
7. A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer.
Yao D; Wang Y; Bian K; Zhang B; Wang D
Biomaterials; 2023 Jan; 292():121920. PubMed ID: 36442436
[TBL] [Abstract][Full Text] [Related]
8. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.
Zhao M; Yang X; Fu H; Chen C; Zhang Y; Wu Z; Duan Y; Sun Y
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32763-32779. PubMed ID: 34235912
[TBL] [Abstract][Full Text] [Related]
9. Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model.
Hu Y; Wang D; Zhang T; Lei M; Luo Y; Chen Z; Li Y; Duan D; Zhang L; Zhu Y
Int J Nanomedicine; 2024; 19():1809-1825. PubMed ID: 38414523
[TBL] [Abstract][Full Text] [Related]
10. The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer.
Zhou Y; Xiao Z; Zhu W
Front Oncol; 2022; 12():998964. PubMed ID: 36212432
[TBL] [Abstract][Full Text] [Related]
11. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
14. Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer.
Fang H; Gai Y; Wang S; Liu Q; Zhang X; Ye M; Tan J; Long Y; Wang K; Zhang Y; Lan X
J Nanobiotechnology; 2021 Mar; 19(1):81. PubMed ID: 33743740
[TBL] [Abstract][Full Text] [Related]
15. A phthalocyanine-based photosensitizer for effectively combating triple negative breast cancer with enhanced photodynamic anticancer activity and immune response.
Huang K; Yan M; Zhang H; Xue J; Chen J
Eur J Med Chem; 2022 Nov; 241():114644. PubMed ID: 35939997
[TBL] [Abstract][Full Text] [Related]
16. Light-inducible nanodrug-mediated photodynamic and anti-apoptotic synergy for enhanced immunotherapy in triple-negative breast cancer.
Huang J; Liu X; Lin M; Xiao Z; Shuai X
Biomater Sci; 2024 May; 12(10):2639-2647. PubMed ID: 38563394
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
18. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of three commercial photosensitizers for efficiency of inducing immunogenic cell death in anti-tumor immunotherapy].
Lin X; Mao D; Bai R
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1791-1798. PubMed ID: 36651246
[TBL] [Abstract][Full Text] [Related]
20. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
